Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Fabio Bettella"'
Autor:
Riccardo Beninatto, Devis Galesso, Matteo Soato, Cristian Guarise, Fabio Bettella, Mauro Pavan
Publikováno v:
Carbohydrate Research. 503:108314
Hyaluronic acid (HA), a naturally occurring biopolymer composed of repeating units of d -glucuronic acid and N-acetyl-glucosamine, is widely used as principal component of drugs, medical devices, nutraceuticals and cosmetics. Chemical modifications o
Autor:
Gilda De Luca, Fabio Bettella, Pierfrancesco Bassi, Claudio Pagano, Davide Renier, Giovanni Esposito, Antonio Rosato, Paola Zanovello, Alessandra Banzato
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 24:207-215
Objective To report the development of a new water-soluble paclitaxel-hyaluronic acid bioconjugate, HYTAD1-p20, for intravesical treatment of superficial bladder cancer. Materials and Methods HYTAD1-p20 was synthesized by carboxyl esterification of h
Pharmacokinetic profile of Oncofid-S after intraperitoneal and intravenous administration in the rat
Autor:
Pierluigi Navarra, Maria Cristina Greco, Giuseppe Tringali, Fabio Bettella, Davide Renier, Monica Campisi
Publikováno v:
The Journal of pharmacy and pharmacology. 64(3)
Objectives Oncofid-S is a bio-conjugate molecule obtained from the binding of campthotecin, SN-38, to hyaluronic acid. In view of a possible clinical development for loco-regional treatment of peritoneal carcinomatosis, this study aimed to establish
Autor:
Savino M. Di Stasi, Pierluigi Navarra, Fabio Bettella, Giuseppe Tringali, Lucia Lisi, Davide Renier
Publikováno v:
Pharmacological research. 58(5-6)
Intravesical instillation of BCG or anticancer agents after transurethral resection is currently considered a standard of therapy. However, this approach is basically empirical; none of the anticancer agents used in this setting was specifically form
Autor:
Antonio Rosato, Sara Bobisse, Davide Renier, Alessandra Banzato, Fabio Bettella, Giovanni Esposito, Luigi Quintieri, Maria Rondina, Laura Meléndez-Alafort, Ulderico Mazzi, Paola Zanovello
Purpose: This study was designed to evaluate the pharmacologic and biological properties of a paclitaxel-hyaluronan bioconjugate (ONCOFID-P) against IGROV-1 and OVCAR-3 human ovarian cancer xenografts following i.p. administration. Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a189caa17f438d59d6eeef7f5b47de9
http://hdl.handle.net/11577/2443970
http://hdl.handle.net/11577/2443970